Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | pyruvate kinase, muscle | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyruvate kinase | pyruvate kinase, muscle | 605 aa | 521 aa | 34.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Pyruvate kinase | 0.004 | 0.8611 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.8611 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.004 | 0.8611 | 0.8611 |
Trypanosoma brucei | pyruvate kinase 1 | 0.004 | 0.8611 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Loa Loa (eye worm) | pyruvate kinase | 0.004 | 0.8611 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Chlamydia trachomatis | pyruvate kinase | 0.004 | 0.8611 | 0.5 |
Mycobacterium tuberculosis | Probable pyruvate kinase PykA | 0.004 | 0.8611 | 0.5 |
Leishmania major | pyruvate kinase | 0.004 | 0.8611 | 0.5 |
Toxoplasma gondii | pyruvate kinase PyK1 | 0.004 | 0.8611 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.004 | 0.8611 | 0.5 |
Mycobacterium ulcerans | pyruvate kinase | 0.004 | 0.8611 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.004 | 0.8611 | 0.5 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.004 | 0.8611 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Echinococcus granulosus | pyruvate kinase | 0.004 | 0.8611 | 0.8611 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.004 | 0.8611 | 0.5 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.004 | 0.8611 | 0.5 |
Echinococcus multilocularis | pyruvate kinase | 0.004 | 0.8611 | 0.8611 |
Leishmania major | pyruvate kinase | 0.004 | 0.8611 | 0.5 |
Loa Loa (eye worm) | pyruvate kinase | 0.004 | 0.8611 | 1 |
Schistosoma mansoni | pyruvate kinase | 0.004 | 0.8611 | 0.8611 |
Mycobacterium leprae | Probable pyruvate kinase PykA | 0.004 | 0.8611 | 0.5 |
Loa Loa (eye worm) | pyruvate kinase | 0.004 | 0.8611 | 1 |
Trypanosoma brucei | pyruvate kinase 1, putative | 0.004 | 0.8611 | 0.5 |
Echinococcus multilocularis | pyruvate kinase | 0.0032 | 0.4884 | 0.4884 |
Schistosoma mansoni | pyruvate kinase | 0.004 | 0.8611 | 0.8611 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.004 | 0.8611 | 0.5 |
Echinococcus granulosus | pyruvate kinase | 0.004 | 0.8611 | 0.8611 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.004 | 0.8611 | 0.5 |
Plasmodium falciparum | pyruvate kinase | 0.004 | 0.8611 | 1 |
Plasmodium vivax | pyruvate kinase, putative | 0.004 | 0.8611 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 2.9063 um | PUBCHEM_BIOASSAY: Secondary assay for Activators of Human Pyruvate Kinase M2 isoform. (Class of assay: confirmatory) [Related pubchem assays: 1634, 1631 ] | ChEMBL. | No reference |
Potency (functional) | 2.9063 uM | PUBCHEM_BIOASSAY: Confirmation Concentration-Response Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase: for Probe SAR. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.